Avalo Therapeutics (AVTX) Notes Payables (2022 - 2025)
Avalo Therapeutics (AVTX) posted Notes Payables of $370000.0 for Q2 2025, up 2.78% on a QoQ basis from $360000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Notes Payables (2022 - 2025) Analysis & Trends
Avalo Therapeutics' Notes Payables history runs 4 years deep, the most recent figure standing at $370000.0 for Q2 2025.
- Quarterly Notes Payables changed N/A year-over-year to $370000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $370000.0 (changed N/A YoY) and the FY2024 annual result came in at $360000.0, changed N/A from the prior year.
- Notes Payables was $370000.0 for Q2 2025 at Avalo Therapeutics, up from $360000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $14.1 million in Q2 2023 and bottomed at $360000.0 in Q4 2024.
- A 4-year average of $4.7 million and a median of $2.6 million in 2022 frame the typical range for Notes Payables.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 370,000.00 |
| Mar 31, 2025 | 360,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Jun 30, 2023 | 14.12 Mn |
| Mar 31, 2023 | 9.30 Mn |
| Dec 31, 2022 | 5.93 Mn |
| Sep 30, 2022 | 2.56 Mn |